Payment overview · 2025
General Payments
$498.86
26 reported records · 10 companies
Healthcare provider profile · identity verified
Marion L Sennett, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MOBILE, AL · NPI 1962498295
Verified facts
What the public records show
CMS Open Payments records show Marion L Sennett, MD received $498.86 in general payments during 2025 across 26 reported records.
Novo Nordisk Inc accounted for 35.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $178.26 | 35.7% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $98.57 | 19.8% | 5 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.77 | 9.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.35 | 8.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.25 | 7.1% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $22.04 | 4.4% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $21.82 | 4.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.21 | 4.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.95 | 3.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.64 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $498.86 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $178.26 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $178.26 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $98.57 | 5 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $44.77 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $42.35 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $35.25 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $22.04 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.95 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 26 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
26 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 663 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 439 | 144 |
| Atorvastatin Calcium | Atorvastatin Calcium | 429 | 140 |
| Losartan Potassium | Losartan Potassium | 229 | 73 |
| Gabapentin | Gabapentin | 220 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 181 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 178 | 61 |
| Metformin Hcl | Metformin Hcl | 167 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 163 | 57 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 159 | 26 |
| Glipizide | Glipizide | 148 | 46 |
| Omeprazole | Omeprazole | 145 | 50 |
| Alprazolam | Alprazolam | 134 | 19 |
| Clonazepam | Clonazepam | 133 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 108 | 43 |
| Pioglitazone Hcl | Pioglitazone Hcl | 100 | 32 |
| Levothyroxine Sodium | Levothyroxine Sodium | 98 | 32 |
| Lisinopril | Lisinopril | 95 | 29 |
| Meloxicam | Meloxicam | 94 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 11 |
| Potassium Chloride | Potassium Chloride | 92 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 86 | 29 |
| Trazodone Hcl | Trazodone Hcl | 83 | 20 |
| Furosemide | Furosemide | 80 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 35 |
| Tramadol Hcl | Tramadol Hcl | 77 | 21 |
| Allopurinol | Allopurinol | 76 | 28 |
| Clonidine Hcl | Clonidine Hcl | 75 | 18 |
| Lorazepam | Lorazepam | 75 | 13 |
| Carvedilol | Carvedilol | 71 | 25 |
| Promethazine Hcl | Promethazine Hcl | 59 | suppressed |
| Simvastatin | Simvastatin | 55 | 16 |
| Metformin Hcl Er | Metformin Hcl | 53 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 18 |
| Methadone Hcl | Methadone Hcl | 48 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 19 |
| Pregabalin | Pregabalin | 47 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 14 |
| Mirtazapine | Mirtazapine | 42 | 18 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Temazepam | Temazepam | 40 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | 11 |
| Ondansetron Odt | Ondansetron | 38 | 13 |
| Diazepam | Diazepam | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Famotidine | Famotidine | 35 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 13 |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Prednisone | Prednisone | 31 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Baclofen | Baclofen | 29 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 28 | 11 |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Ozempic | Semaglutide | 26 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Eliquis | Apixaban | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Thiothixene | Thiothixene | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | 11 |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $498.86 · 26 records | Novo Nordisk Inc | Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, GVOKE HYPOPEN, Kerendia, Omnipod, Ozempic, REXULTI, Rybelsus, ZORYVE | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error